Evolent Health (NYSE:EVH – Get Free Report) and Firefly Neuroscience (NASDAQ:AIFF – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.
Institutional & Insider Ownership
5.0% of Firefly Neuroscience shares are owned by institutional investors. 1.5% of Evolent Health shares are owned by company insiders. Comparatively, 6.9% of Firefly Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings and recommmendations for Evolent Health and Firefly Neuroscience, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evolent Health | 1 | 4 | 11 | 0 | 2.62 |
| Firefly Neuroscience | 1 | 0 | 0 | 0 | 1.00 |
Valuation and Earnings
This table compares Evolent Health and Firefly Neuroscience”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evolent Health | $1.88 billion | 0.28 | -$534.51 million | ($4.57) | -1.01 |
| Firefly Neuroscience | $1.80 million | 9.42 | -$19.88 million | ($0.59) | -1.83 |
Firefly Neuroscience has lower revenue, but higher earnings than Evolent Health. Firefly Neuroscience is trading at a lower price-to-earnings ratio than Evolent Health, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Evolent Health and Firefly Neuroscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evolent Health | -24.08% | -4.27% | -1.06% |
| Firefly Neuroscience | -506.23% | -90.17% | -72.05% |
Volatility & Risk
Evolent Health has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Firefly Neuroscience has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.
Summary
Evolent Health beats Firefly Neuroscience on 9 of the 14 factors compared between the two stocks.
About Evolent Health
Evolent Health, Inc., through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides holistic total cost of care management. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
About Firefly Neuroscience
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.
